Evaluation of Sovodak (sofosbuvir/daclatasvir) treatment outcome in COVID-19 patients compared with Kaletra (lopinavir/ritonavir); a randomized clinical trial

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and treatment are significant health organizations’ concerns worldwide. Although there is no proven drug license against the virus, a variety of components have under investigation. Objectives: In this regard, present study was intended to evaluate consequences Sovodak (sofosbuvir/ daclatasvir) in COVID-19 patients compared with Kaletra (lopinavir/ritonavir). Patients Methods: This conducted as randomized trial using 120 COVID19 confirmed cases between August 19th September 19th, 2020, which subjects were classified into two groups, 58 (Sovodak group) 54 (Kaletra group). Related statistical operations calculated outcomes such survival rate hazard ratio by SPSS version 16. composed sofosbuvir 400mg daclatasvir 60mg, included lopinavir 400 mg ritonavir 100 mg. Results: We observed that difference concerning comorbidities, death, intensive care unit admission, remission. Besides, had higher discharge versus [HR=1.551 (95% CI=1.008-2.386), P =0.046] better outcome receiving. Conclusion: Hazard plot. (sofosbuvir/daclatasvir) therapy accompanied significantly than Trial Registration: has been registered Iranian Registry Clinical Trials (identifier: IRCT20200328046885N1; https://en.irct.ir/trial/47565, Ethical code #IR.IUMS.FMD.REC.1399.407).